Microvillus inclusion disease (MVID) is a congenital intestinal disorder characterized by chronic, severe, and watery diarrhea due to insufficient absorption of nutrients during digestion. Two forms of MVID have been identified: early-onset MVID, which develops within hours or days of birth, and late-onset MVID, which occurs in the first months of life1. Affected infants experience malnutrition, dehydration, developmental delays, and severe metabolic acidosis. The cause of MVID is unknown, however, the disease can be attributed to mutations in the MYO5B gene which result in abnormal microvilli, which reduce the intestine’s ability to absorb necessary nutrients and fluids. While the exact prevalence of MVID is unknown, the disease is extremely rare with less than 200 cases reported in Europe since it was first described in 1978 by GP Davidson3. No medical treatment has been successful in overcoming MVID-associated intestinal failure. Affected infants remain dependent on total parenteral nutrition or intravenous replacement of fluid and electrolytes life-long4. Due to the severity of the disease, the prognosis for MVID is poor as a result of severe dehydration, metabolic imbalance, and sepsis5.
- Microvillus inclusion disease. Genetics Home Reference. https://ghr.nlm.nih.gov/condition/microvillus-inclusion-disease. Accessed July 12, 2019.
- RESERVED IU–AR. Orphanet: Microvillus inclusion disease. https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=2290&lng=EN. Accessed July 12, 2019.
- Towards understanding microvillus inclusion disease. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733813/. Accessed July 12, 2019.
- Bunn SK, Beath SV, McKeirnan PJ, et al. Treatment of Microvillus Inclusion Disease by Intestinal Transplantation. Journal of Pediatric Gastroenterology and Nutrition. 2000;31(2):176.
- Ruemmele FM, Schmitz J, Goulet O. Microvillous inclusion disease (microvillous atrophy). Orphanet J Rare Dis. 2006;1:22. doi:10.1186/1750-1172-1-22
BioPharma Global is a mission-driven corporation, operating like a not-for-profit, dedicated to using our FDA and EMA regulatory expertise and knowledge of various therapeutics areas to help drug developers advance treatments for the disease communities with a high unmet medical need. If you are a drug developer seeking regulatory support for Orphan Drug designation, Fast Track designation, Breakthrough Therapy designation, other FDA/EMA expedited programs, type A, B (pre-IND, EOPs), or C meeting assistance, or IND filings, the BioPharma Global team can help. Contact us today to arrange a 30-minute introductory call.